Protein biomarkers, particularly GFAP and UCH-L1, have achieved sufficient clinical validation to enable routine use in acute care settings, as evidenced by FDA approval of the Banyan Brain Trauma IndicatorTM [86]. This evidence concerns the gene GFAP and brain injury.